Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.
Search results for: rituximab
Evaluation & Treatment of Systemic Sclerosis-ILD in the New Decade
ACR Convergence panelists discussed how to monitor SSc-ILD patients for ILD severity & the brightening prospects for therapy.
The 2020 ACR Review Course: Key Issues Rheumatologists Face
The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.
The 2020 ARP Merit Awards & ACR Distinguished Fellows
During ACR Convergence 2020 in early November, the ACR and ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARP Merit Awards and the ACR’s Distinguished Fellows. In addition, we bring you the first ever…
Medicare’s Most Favored Nation Is My Least Favorite Notion!
In case you missed it, on Nov. 20, the Centers for Medicare & Medicaid Services (CMS), a department within the U.S. Department of Health and Human Services, announced that it will overhaul the payment system for Medicare Part B (i.e., infusion) drugs on Jan. 1, 2021. The plan is called the Most Favored Nation (MFN)…
A Year to Remember: Dr. Jinoos Yazdany Presents the 2020 Clinical Research Review
During ACR Convergence 2020, Jinoos Yazdany, MD, MPH, discussed innovative research into a potential treatment for lupus, medication tapering & more. These findings may influence the treatment of rheumatic disease in the future.
Resetting Immune Tolerance to Prevent RA
Three experts discuss the current evidence on potential pathogenic mechanisms underlying preclinical RA autoimmunity and subsequent active disease.
Experts Discuss Unique Challenges Posed by Difficult-to-Treat RA
ACR CONVERGENCE 2020—Patients with rheumatoid arthritis (RA) and concurrent liver disease or interstitial lung disease (ILD), or with treatment-refractory RA, pose treatment challenges, said panelists in the ACR Convergence 2020 session, How I Treat Difficult RA. Each panelist discussed a difficult case and raised big-picture questions on how to best treat patients facing each challenge….
Dr. Blair Solow’s Picks for the Top RA Research Presented at ACR Convergence 2020
ACR CONVERGENCE 2020—Held Nov. 5–9, the ACR’s first fully virtual annual meeting provided participants with a vast repository of new research related to rheumatoid arthritis (RA). To help you sort through the noise, Elizabeth (Blair) Solow, MD, an assistant professor of medicine in the Division of Rheumatic Diseases at UT Southwestern Medical Center, Dallas, offered …
ACR Introduces Draft Guideline for RA Management
Treating RA can be complicated, especially if the patient is suffering from comorbidities. In a session at ACR Convergence 2020, experts discussed the development of a new ACR draft guideline for RA management & how it can be applied in real-life clinical practice.
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 45
- Next Page »